Abstract
Astragaloside IV (AS-IV) has been reported to possess anti-metastasis activity in cancer cells. However, it is unknown whether AS-IV could inhibit epithelial-mesenchymal transition (EMT), a cellular de-differentiation program that promotes metastasis, in cancer cells. The aim of this study was to study the effect and mechanism of AS-IV on EMT in gastric cancer (GC) cells. The results showed that AS-IV significantly inhibited cell viability, invasion, and migration of GC cells. The E-cadherin to N-cadherin switch and expression of Vimentin and metastasis-related genes were induced by transforming growth factor β1 (TGF-β1), whereas AS-IV reversed the induction. In addition, AS-IV inhibited TGF-β1-induced activation of PI3K/Akt/NF-κB. Inhibition of the PI3K/Akt/NF-κB pathway reversed TGF-β1-induced EMT. In conclusion, AS-IV inhibited TGF-β1-induced EMT through inhibition of the PI3K/Akt/NF-κB pathway in GC cells. AS-IV might be an effective candidate for the treatment for GC.
References
May 26, 2006·Nature·Gerhard Christofori
Jun 15, 2007·Pathology·Marcello GuarinoGianmario Ballabio
Jun 3, 2009·The Journal of Clinical Investigation·Raghu Kalluri, Robert A Weinberg
Jan 12, 2011·Cancer Science·Chun-Yu LinMing-Ting Lee
May 24, 2011·Oral Oncology·Xinhua Liang
Jul 12, 2011·Annual Review of Cell and Developmental Biology·M Angela Nieto
Oct 10, 2012·Oncogene·Z LiuD Xu
Sep 13, 2013·Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan·Shuang RenPing Liu
Jan 7, 2014·Chemical & Pharmaceutical Bulletin·Yuanyuan JiaYingliang Wu
Mar 13, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Parisa KarimiFarin Kamangar
Jul 2, 2014·Journal of Cancer Research and Clinical Oncology·Anle ZhangJianhui Tian
Aug 26, 2014·Oncotarget·Sitai LiangSamy L Habib
Sep 15, 2014·International Immunopharmacology·Xudong ChengXiaobin Jia
May 31, 2016·Experimental Cell Research·Simona DinicolaMariano Bizzarri
Aug 28, 2016·Fundamental & Clinical Pharmacology·Lei LiMenbayaer Tu
Dec 9, 2016·International Immunopharmacology·Ke JiangXiaohong Xue
Jan 22, 2017·Oncology Research·Ning WuTao Ma
Jan 24, 2017·Oncology Reports·Cheng-Dong QinZhao-You Tang
Mar 10, 2017·Cellular and Molecular Gastroenterology and Hepatology·Bryson W Katona, Anil K Rustgi
Jun 1, 2017·Medical Oncology·Elena Prieto-GarcíaM Teresa Agulló-Ortuño
Jul 27, 2017·OncoTargets and Therapy·Shu-Jin HeLi-Xia Xiong
Citations
Mar 11, 2020·Bioscience, Biotechnology, and Biochemistry·Jinming HanLeijie Zhou
Apr 24, 2020·Journal of Cellular Physiology·Tulika Mitra, Rahul Bhattacharya
Jun 13, 2020·The Journal of International Medical Research·Jianxin LiuJiumao Lin
Jul 30, 2020·Phytotherapy Research : PTR·Ruirui LuJunbiao Wu
Sep 24, 2020·Phytotherapy Research : PTR·Yue GaoXianli Meng
Sep 25, 2018·Journal of Cellular Biochemistry·Honglei WangMin Xu
Feb 29, 2020·FEMS Microbiology Letters·Jing ZhangZhijun Jie
Apr 27, 2020·Chinese Journal of Integrative Medicine·Yuan-Shen ZhouMin-Zhou Zhang
Nov 30, 2018·International Journal of Molecular Medicine·Xiao ChenDongdong Wang
Sep 6, 2019·Molecular Medicine Reports·Weiwei ZhuXufang Wang
Nov 18, 2018·Cancer Medicine·Ziyu ZhuYiwen You
Mar 27, 2019·International Journal of Molecular Sciences·Zhenzhen GuoJinjun Wu
Jan 2, 2021·International Journal of Molecular Sciences·Joanna KozakJacek Baj
Jan 1, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Baoyi LiuZhouwei Wu
Jan 21, 2021·Drug Design, Development and Therapy·Jingyu XuXuan Zhang
Nov 20, 2020·BMC Genomics·Xueting WuXuan Li
Jun 15, 2021·Immunopharmacology and Immunotoxicology·Wei LiuDongsheng Wang
Aug 24, 2021·Frontiers in Molecular Biosciences·Huichen ZhaoXiao-Bing Chen
Jul 11, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wei YuMengfei Zhong